DoD Reconstructive Transplant Research, Investigator-Initiated Research Award | HT942524RTRPIIRA

Opportunity Information: Apply for HT942524RTRPIIRA

The FY24 DoD Reconstructive Transplant Research Program (RTRP) Investigator-Initiated Research Award is a grant opportunity from the U.S. Army Medical Research Acquisition Activity (USAMRAA) that supports investigator-driven studies aimed at advancing reconstructive transplantation, improving patient care, and ultimately enhancing quality of life. While the program is open to groundbreaking ideas, proposals are expected to be firmly grounded in strong scientific rationale and must clearly connect to real-world military needs, particularly for Service Members and Veterans recovering from traumatic injuries. The overall intent is to fund research that can meaningfully move the field of vascularized composite allotransplantation (VCA) forward, whether through new biological insights, better diagnostic approaches, improved clinical management strategies (outside of interventional trials), or other innovations aligned with the program's focus areas.

A central expectation of this award is rigor in study design and feasibility. Applications need to lay out a clear, well-justified research plan that is reproducible and realistically translatable. Reviewers will be looking for details that show the work can be executed as proposed, including an appropriate statistical approach and power analysis when relevant. If the project uses a model system, it needs to be a good match for the scientific questions and, importantly, applicable to VCA. The opportunity also emphasizes widely accepted principles for rigorous experimental design and reporting, including practices like randomization, blinding, sample-size estimation, and transparent data handling, reflecting standards intended to improve reproducibility and the likelihood that preclinical findings translate into clinical value.

Impact is another major pillar of the award. Applicants must clearly explain the expected short- and long-term contributions of their work and tie those contributions to at least one of the FY24 RTRP Investigator-Initiated Research Award Focus Areas (the specific focus areas are referenced in the announcement and must be addressed directly). The program is looking for studies that can shift understanding or practice in reconstructive transplant research rather than incremental work without a clear line to future benefit. Military relevance is non-negotiable: projects must be responsive to the health care needs of injured Service Members or Veterans and may also consider effects on family members, caregivers, and clinicians, as well as broader public benefit. Collaboration with military researchers and clinicians is encouraged because it can strengthen practical relevance and access to populations or infrastructure, but it is not required.

Applicants are expected to include preliminary or published data that supports the rationale for the proposed work. The program recognizes that early signals can come from many sources, including laboratory findings, population-level observations, clinician experience, or even anecdotal evidence, but the application still must present evidence that credibly motivates the research direction. The announcement also makes clear that it is acceptable to leverage discoveries from solid organ transplantation and test or adapt them in a VCA context, as long as the application explains why this translation is justified. For example, applicants should clarify why outcomes might differ in VCA, why confirming similarity matters, or how repeating or adapting the work in VCA could uncover mechanisms unique to composite tissue transplantation.

The scope of allowable research is broad, spanning basic through translational science. That can include preclinical animal studies, observational clinical research involving human subjects, and studies using human anatomical substances, as well as correlative studies tied to an existing clinical trial. However, one of the most important restrictions is that clinical trials are not allowed under this funding opportunity. The announcement uses the federal definition of a clinical trial (prospective assignment of human subjects to an intervention to evaluate biomedical or behavioral outcomes). Observational clinical research is allowed, including studies on disease mechanisms, biomarker or imaging-based diagnostic work, health disparities, technology development, epidemiology, behavioral research not assessing intervention effects, and outcomes or health services research, as long as they do not evaluate the safety, effectiveness, or efficacy of an intervention. The announcement also clarifies limits around certain in vitro studies using unidentifiable human specimens that may be exempt under the Common Rule.

The RTRP also signals interest in research that improves understanding of women's health in this area. Consistent with CDMRP priorities, applicants are encouraged to consider conditions and outcomes that affect women uniquely, disproportionately, or differently than men, including incorporating sex as a biological variable where appropriate and explaining how findings could improve outcomes or advance knowledge related to women's health in reconstructive transplantation.

From a team structure standpoint, the award includes a Multiple Principal Investigator option, allowing up to four PIs. One PI serves as the Initiating PI and handles most submission and administrative responsibilities, while the others serve as Partnering PIs who must meaningfully contribute to planning and execution. If funded, each PI is named on a separate award to their organization, with separate reporting and administrative requirements, which is important for teams spanning multiple institutions.

The DoD encourages use of Department of Defense and/or Department of Veterans Affairs resources where relevant, and it strongly encourages multidisciplinary partnerships across academia, industry, the military services, the VA, and other federal agencies. If an application depends on special resources (such as unique databases, infrastructure, or access to specific populations), the proposal needs to document that access at the time of submission and explain how access will be maintained throughout the project.

Administratively, awards are made as grants under 31 USC 6304. The anticipated budget cap for total costs across the full period of performance is up to $1.0 million for single-PI applications and up to $1.5 million for projects submitted under the Multiple PI option. The program expects to allocate about $4.0 million total to fund roughly three awards, though actual funding depends on federal availability and the merit of submissions as determined by peer and programmatic review. The original application closing date listed is October 23, 2024. Awards supported with FY24 funds are expected to be made no later than September 30, 2025, and the FY24 funds are anticipated to remain available for use until they expire on September 30, 2030. Finally, awardees should expect ongoing oversight and engagement, including the possibility of being invited to present progress at the program's annual virtual In-Progress Review meetings.

• The Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Reconstructive Transplant Research, Investigator-Initiated Research Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on 2024-06-27.
• Applicants must submit their applications by 2024-10-23. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 3 candidate(s).
• Eligible applicants include: Unrestricted.

Apply for HT942524RTRPIIRA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: